Top Journal Scans

Kim A. Eagle, MD, MACC
Editor-in-Chief, ACC.org

In 2023, we continued to see advances in global health technology. These technologies provide a means to prevent, diagnose and treat cardiovascular disease and may also hold the keys to addressing health equity and improving clinician well-being.

We saw the most visited journal scan content on ACC.org focusing on myocardial infarction, heart failure, atrial fibrillation, as well as prevention.

ACC.org is a hub for concise and easily digestible content, focusing on key summary documents such as guidelines and consensus statements.

In 2023, we saw release of expert consensus on management of HFpEF and cardiac amyloidosis, new atrial fibrillation guidelines, new guidelines for chronic coronary disease, as well as reviews of digital health technologies, a summary statement on sudden cardiac arrest in young athletes, and an expert analysis on why cuff size is so important and other factors that affect accurate blood pressure measurement.

The ACC looks forward to opportunities in 2024 to partner with you and provide you with cutting edge information for your practice!

— Kim A. Eagle, MD, MACC

Top Journal Scans

1. Aspirin vs. Clopidogrel for Long-Term Maintenance After PCI
2. Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis
3. Cardiovascular Safety of Testosterone-Replacement Therapy
4. Carvedilol vs. Metoprolol and Risk of Arrhythmias Among ICD Recipients
5. Switching From VKA to NOAC in Frail Patients With AF: FRAIL-AF Trial
6. PCI or CABG for Left Main Coronary Artery Disease
7. Exercise Volume vs. Intensity and Coronary Atherosclerosis Progression
8. Acute Effects of Coffee Consumption on Health
9. Fate of the Unoperated Ascending Aortic Thoracic Aneurysm
10. SCORE2-Diabetes: 10-Year Cardiovascular Risk Estimation

Dharam J. Kumbhani, MD, SM, FACC

Anthony A. Bavry, MD, MPH, FACC

Editors, Clinical Trials and News, ACC.org

Top Clinical Trials

It was an exceptional year for trial coverage on ACC.org!

There were 210,000 unique views of the top trials and top trial updates for the year.

Treatment of heart failure and of coronary artery disease were hot topics.

Practice changing trials were covered throughout the year. Including trials in coronary imaging, transcatheter tricuspid valve interventions, transcatheter aortic valve implantation (TAVI) and further insights from the REVIVED-BCIS2 study are among the top research that came out of 2023 in interventional cardiology field.

Additional perspectives were found in the SELECT trial where results showed semaglutide reduced cardiovascular events by 20% in adults overweight or obese and established cardiovascular disease who do not have diabetes, according to new research. The EXPLORER-HCM trial showed that mavacamten was superior to placebo at improving exercise capacity and health status.

In addition to covering new trials, we continue to update prior trials with any related significant presentations or publications.

We successfully provided at least three visual abstracts for some of the key trials at the major meetings this year. We are continuing to strive to make ACC.org a very user-friendly educational portal.

On behalf of the ACC.org staff, Happy Holidays, and a joyous New Year to you all!

— Dharam J. Kumbhani, MD, SM, FACC and Anthony A. Bavry, MD, MPH, FACC

Top Clinical Trials

1. LODESTAR: Rosuvastatin vs. Atorvastatin Treatment in Patients With Coronary Artery Disease
2. CLEAR Outcomes: Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen
3. BIOVASC: Percutaneous Complete Revascularization Strategies Using Sirolimus-Eluting Biodegradable Polymer-Coated Stents in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease
4. ELAN: Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischemic Stroke Patients With Atrial Fibrillation
5. NOAH-AFNET 6 Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes
6. SELECT: Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
7. RENOVATE-COMPLEX-PCI: Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention
8. ARTESIA: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Subclinical Atrial Fibrillation
9. ATTRibute-CM: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
10. AZALEA-TIMI 71: A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation

Top Clinical Trial Updates

1. REVIVED-BCIS2 (Update): Revascularization for Ischemic Ventricular Dysfunction
2. EXPLORER-HCM (Update): Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
3. DAPA-HF  (Update): Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction
4. STRONG-HF  (Update): Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies
5. ISCHEMIA (Update): International Study of Comparative Health Effectiveness With Medical and Invasive Approaches
6. COAPT (Update): Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation
7. DELIVER (Update): Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure
8. VALOR-HCM (Update): Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
9. Evolut Low Risk (Update): Evolut Surgical Replacement and Transcatheter Aortic Valve Implantation in Low Risk Patients
10. EMPA-KIDNEY (Update): Study of Heart and Kidney Protection With Empagliflozin